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ABSTRACT 
With the rapid pace of development in industrial sector, the pharma sector and researchers involved are equally contributing in developing the 
latest technology for the growth and development. The computer-aided designs and manufacturing that provides 3 Dimensional printed dosage 
forms is the new step being taken into consideration. With the FDA approval to first 3D printed tablet in August 2015, Spritam, 3 Dimensional 
printing (3DP) has become the all new method for preparation of drug delivery system. 3D printing has the capability of dispensing the drug more 
accurately, precisely, and the layer by layer assembly helps in forming complex composition and geometries. 3D printing enables the preparation of 
personalised dosage form and tailored release profiles. 3D printing can be seen as future of solid dosage forms produced on demand, with 
customised dose and possibly lower in cost. It can help in reducing side effects caused by excessive doses. This review highlights the 3D printing 
technology and its applications in growth of pharmaceutical sector. An overview of reviews was conducted to locate published literature between 
2000 and 2017.  
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In the past decade, the use of 3D printers has grown dramatically for 
both industries and public. There has been increase in global sales of 
consumer based printers by more than 33% over last 3 y, worth $4.1 
billion in 2014 [1]. The most renowned, distinct and novel solid 
dosage forms have been found to be fabricated by variety of three-
dimensional printing (3DP) technologies [2-4]. 3DP or additive 
manufacturing (AM) is a process of making three dimensional solid 
objects from a digital file [5]. 3DP is unique and powerful technology 
that was first described by Charles Hull in 1986 and called it as 
“stereolithography” [6]. It uses “.stl file format” to interpret the data 
in Computer Aided Design file. These data instructions are then 
electronically communicated to the 3D printer [7]. These 
instructions include the shape, size, texture, thickness of the object 
to be printed [8]. Hull later founded his own company as “3D 
system” where he designed a stereo lithography based 3D printer 
and was commercially available in market in 1988 [5]. Since then 
many companies developed 3D printers for commercial application. 
In 1987, Carl Deckard filed a patent for the selective laser sintering 
(SLS) rapid prototyping process in US and was issued in 1989. In the 
same year, Scott Crump, a co-founder of Stratasys Inc. filed a patent 
for a technology that is still used by the company i. e, fused 
deposition modelling (FDM) and was issued in 1992 [9]. Hans 
Langer founded the EOS GmbH in Germany and further focused on 
the laser sintering (LS) process and now it is well known around the 
world for their quality outputs and applications in 3D printing and 
still is continuing to strengthen the production applications. 
Throughout the 1990’s and early 2000’s a host of new technologies 
continued to be introduced. The Solidscape and ZCorporation, 
Arcam, Object Geometries, MCP Technologies, EnvisionTec and 
ExOne were set up in 1996, 1997, 198, 2000, 2002 and 2005. These 
companies speeded the development of 3D printing across a global 
market. The terminology for all the applications was accepted to be 
additive manufacturing. These technologies were large, very 
expensive for small enterprises or individuals. However, in the last 
decade many new companies entered the market with small, 
cheaper and high quality machines. The first small kit form 3D 
printer was made available in 2009, for the commercial application 
based on RepRap concept. Furthermore, in June 2012, alternate 
process of 3D printing utilising DLP technology “B9Creator” was 
introduced. In same year, Form 1 was introduced utilising 
stereolithography [10]. From then, much more growth was observed 
in this field and the fact was demonstrated that the 3DP is having 
commercial applications in various industrial sectors. 3DP expanded 
rapidly and revolutionized health care as well [12]. The medical use 
of 3DP includes: creation of custom prosthetics, body tissue, organ 
fabrication, anatomical models, dental implants, pharmaceutical 
research regarding drug dosage forms, drug delivery and discovery 
[11]. In December 2015, the FDA had approved more than 85 3D-
printed medical devices [12]. Moreover, FDA also granted approval 
to first 3D printed tablet, Spritam (levetiracetam), manufactured by 
Aprecia Pharmaceuticals in 2015 [13]. Aprecia’s product ‘Spritam’ is 
used to treat epilepsy, which showed a significant advancement for 
patients suffering from seizures. With this landmark milestone in 3D 
Pharming in market, the future of drug manufacturing could change 
drastically [9].  
3DP is a layer-by-layer process capable of producing 3D drug 
products from digital design [14]. 3DP technology based on 
computer aided design is used to achieve unparalleled flexibility, 
save time, and exceptional manufacturing capability of 
pharmaceutical drug products, to formulate drug materials into the 
desired dosage form [15]. The process involves 3D proto-typing of 
layer-by-layer fabrication (via computer-aided design models) to 
formulate drug materials into the desired dosage form. 
The Principle behind a 3D printer can be assumed to be similar to a 
regular printer. 3D printer consists of an extruder that moves 
horizontally on an axis which is held on top of two axes that allow it 
to move back and forward in x-y plane to create the base of the 
object [6]. These two axes are attached to the sides of the printer. 
The only difference is the 3D printer has a base that moves vertically 
along the z axis to create the layers over the object. While printing 
the first layer the extruder remains at the top and moves only in 2D. 
The base that holds the substrate will decrease in height so that next 
layer could be built upon it. The process is repeated following the 
computer-aided drafting instructions until the object is built layer by 
layer. This process is referred to as additive manufacturing, rapid 
prototyping (RP), or solid freeform technology (SFF) [16]. 3D 
printers are used to print various porous scaffolds with controlled 
chemistry, interconnected porosity and special shapes. These prints 
are biodegradable and proved to be ideal for drug delivery abilities 
[17-21]. Some of the highly complex structures incorporating living 
cells can be created by this technique and has gained popularity and 
applicability in cancer treatment [22-25]. 
Different types of drug delivery systems such as oral controlled 
release systems, micro pills, microchip, drug implants, fast 
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dissolving tablets and multiphase release dosage forms have been 
developed using 3DP technology [26-31]. Conventional methods for 
designing the dosage form for drug delivery includes multiple 
manufacturing steps such as granulation, extrusion or coating [32]. 
However, with rise in market novel manufacturing technologies such 
as nano, micro-scale medicines, biomimetic particles, systemised 
liposomes, niosomes have emerged to be successful in saving cost 
and time [33-35]. Thus, 3D printing naturally appeared to be an 
important tool in fulfilling the current requirements of the industry 
[36-38]. 3D printing tool can be considered as an essential tool for 
designing simple as well complex, accurate, cost effective, 
structured, self-designed and controlled release drug delivery 
systems [39-43]. Various technologies are used for 3D printing in 
drug dosage form development [16]. These technologies are: Inkjet 
printing, Fused deposition modelling, Stereolithography (SLA), 
Direct energy deposition, Direct write, Zip dose, Thermal inkjet, 
Selective laser sintering [44]. In inkjet printing, combination of 
active pharmaceutical ingredients and excipients are precisely 
sprayed on the substrate or base and are solidified to obtain desired 
product. In Fused deposition modelling the filament is melted in the 
head of the 3D printer through induced current heating and then a 
3D structure is created by adding layer by layer [10]. 
Stereolithography is the technique in which a computer controlled 
laser beam is used to solidify the liquid polymer or resin, thereby 
creating 3D structure. [44] In directed energy deposition process a 
printing apparatus consist of a multi-axis robotic arm with a nozzle, 
an energy source (laser, electron, or plasma), and a substrate to 
deposit melted material. For creating a 3D structure, the melted 
materials by the energy source are deposited on the substrate 
through nozzles, and then harden [45]. In Direct-write assembly a 
computer controlled translational stage is used that moves a 
pattern-generating device in order to achieve, layer by layer, the 
desired 3D microstructure [46]. In zip dose method, aqueous fluid is 
used to bind the layers of powder together and method is repeated 
to get desired product. In thermal inkjet printing, the aqueous ink 
fluid is converted to vapour form through heat and moved out of 
nozzle resulting in droplet form. Selective laser sintering uses small 
particles (powder) of polymer, glass, or ceramic that is fused 
together by high power laser heat to form a 3D structure. In sheet 
lamination technology, the external force, heat and pressure is used 
to add material in layers. These layers are then cut into desired 
shapes with the help of laser or blade and a 3D structure is created. 
The 3D printer as a valuable tool is used to create customised 
medications with tailored release profiles and changing the way 
patients take their medications. It could easily create polypill 
containing all the medication needed to cure chronic disease in 1 
pill. The 3D printing in medical field has found to provide many 
benefits, such as customization and personalization of medical 
products, drugs, and equipment; advancement in release pattern, 
cost effectiveness, increased productivity and the democratization of 
design and manufacturing [4]. Moreover, 3D printing technologies 
may transform pharmacy practice by allowing medications to be 
truly individualized and tailored specifically to each patient, 
although technical and regulatory hurdles remain. Further study and 
use of 3D printing technology may offer an important benefit to 
patients who need medications that have narrow therapeutic indices 
or a higher predilection to be influenced by genetic polymorphisms. 
Pharmaceutical drug research and development could be improved 
drastically by 3D printing. 
Historical journey of 3D printing 
In 1996, the very first experiment was conducted on 3D pharming 
by printing multi delivery device. Methylene blue and alizarin yellow 
dyes were positioned in the 3D form in the device; its microstructure 
and composition were manipulated and was made controlled 
release. A square pattern of polyethylene oxide (PEO) was printed 
and dyes were localised in the square. A top and bottom sheet of 
Poly caprolactone was printed to seal it and prevent diffusion. This 
device showed a multiphasic release profile of dyes [13].  
The drug release of tablet (3D printed) can be manipulated by 
changing the chemical properties and composition of binder. A 
cationic methacrylic ester (Eudragit E-100) was used to fabricate 
cellulose tablets. Eudragit RLPO was used to formulate tablets of 
controlled release profiles. It was noted that the increase in binder 
concentration within tablet increased the drug release time which 
was demonstrated by dissolution studies in stimulated intestinal 
fluid. The hardness and friability of the 3D printed tablet were 
comparable to commercially available compressed tablets [6]. E-100 
and Eudragit RLPO were used as binder to fabricate 
chlorpheniramine to make immediate-extended release tablet 
respectively. The immediate release (IR) section delivered the drug 
within the first 30 min of dissolution process. The extended release 
(ER) section delivered the drug for a period of 6 h.  
A diclofenac tablet was designed consisting of 2 sections with varied 
binders in both sections. First section was fabricated using E-100 
which is sensitive to the low pH found in gastric fluid and release 
within stomach whereas Eudragit L-100 which is sensitive to pH 
values above 6 and release within intestinal fluid [9]. Endoephedrine 
hydrochloride was used to fabricate cubic drug delivery devices with 
a near zero controlled release profile. The device consisted of 
hydroxypropyl methyl cellulose (HPMC) and Kollidon SR as main 
materials, 15% triethyl citrate solution as shell portion in ethanol as 
binder and 50% by weight of Pseudoephedrine HCl was printed in 
the inner cubic core. The drug released by diffusion of drug present 
in inner core. Active ingredient 68% of acetaminophen and main 
excipients were pre-mixed in the powder bed. Further, a top and 
bottom of the cylindrical device was printed with insoluble layers to 
achieve zero order release [9]. Fast dissolving tablet were prepared 
with compact layers at the top, bottom and lateral layers and loose 
powder with binder inside the pill to increase the stability of the pill. 
The disintegration time was found to be 23.4 s and in vitro 
dissolution showed release within 2 min [47].  
Extrusion 3D printing concept was used to fabricate tablet containing 
Guaifenesin as expectorant. The tablet contained HPMC 2910 as 
binder, microcrystalline cellulose and sodium starch glycolate as 
disintegrant in one portion and make it immediate release 
compartment. The other portion of tablet consisted of HPMC 2208 and 
poly acrylic acid as hydrophilic matrix processed separately and active 
ingredient was combined to form 2 viscous pastes used as feedstock. 
This portion was achieved as sustained release compartment [9]. 
Furthermore, a multiple drug release profile tablet was formulated in 
which three different drugs: captopril, nifedipine and glipizide were 
used to formulate the tablet. The formulation was evaluated for 
dissolution and it was found that captopril showed zero order release 
of an osmotic pump whereas, nifedipine and glipizide showed either 
first order release or Korsmeyer-Peppas release kinetics depending on 
the active/excipient ratio used [6].  
Classification of 3D printing 
Inkjet printing method 
In this method, combination of active pharmaceutical ingredients 
and excipients are precisely sprayed on the substrate in the form of 
droplets based on two techniques, that is, continuous and drop on 
demand. In continuous jet printing, the stream of droplets are 
continuously sprayed on the substrate or deviated towards the 
waste line when not in use. However, in drop on demand method, 
the required amount of droplets are sprayed on the substrate and 
closed when not in need. This makes it more useful and prevents 
wastage that cannot be obtained in continuous jet printing [9]. Inkjet 
printing was used to fabricate controlled release tablet of felodipine 
as hypertensive and polyvinyl pyrrolidine as an excipient [6].  
Fused deposition method 
FDM was the technique patented by Scott Crup, co-founder of 
Stratasy ltd and was developed due to the limitations found in inkjet 
printing. This involves the melting of the raw material or polymers, 
extrusion and layer by layer deposition. Then the material is 
solidified and the desired object is formed. The shape and pore size 
of the object can be varied by varying the raster thickness, angle, 
space between raster and rheological properties [48]. This method 
can be used for manufacturing solid dosage forms such as zero order 
release tablets, multi layered tablets, fast dissolving tablets. Fused 
deposition modelling technique was used to fabricate a tablet of 
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prednisolone loaded poly vinyl alcohol (PVA) filaments with 
extended release [6].  
Direct inkjet writing method 
Direct inkjet writing helps in designing a complex 3D shaped tablet 
or any other object without the need of any expensive equipment or 
tooling. This gives finer sized structures and shapes. This method 
acquires a computer controlled stage, in which a pattern generated 
device or ink deposition nozzle moves to create product with 
controlled 3D shapes and size. Various ink designs are employed in 
direct writing technique such as colloidal suspension, gels, waxes, 
dilute fluids, polymer melts etc. These inks are then solidified by 
either of following methods: liquid evaporation, gelation or solvent 
and temperature phase changes [46]. 
Zip dose method 
This technique was developed by MIT in late 1980’s. In this method 
aqueous fluid is used to bind the layers of powder together. This 
technique is used for formulating a tablet with high dose and rapid 
disintegration [49]. In this process, a layer of powder is deposited as 
a substrate and a liquid or binding fluid is applied to form 
interaction between the powder and liquid binder. This process is 
repeated several times, until desired product of optimal size and 
shape is produced. This leads to formation of highly porous dosage 
form and with high drug loading. 
Thermal inkjet printing method 
This type of printers have a resistor that produces heat when 
current is induced, this heat, heats up the aqueous ink fluid which 
converts it into vapour form that moves out of a nozzle resulting in 
droplet form. This technique requires high temperature that may 
degrade the heat sensitive material. So this factor reduces its 
pharmaceutical applications [50, 51]. Since 2010, the American 
Society for Testing and Materials (ASTM) group ―ASTM F42–
Additive Manufacturing, developed précised set of standards to 
classify the Additive Manufacturing processes into different 
categories [5]. These are as follows:  
Binder deposition method 
In this process, the inkjet printers spray formulation of drug or 
binder onto the powder bed in the form of small droplets at 
optimum speed. The liquid formulation is the binder which is 
available in the printer whereas the API and excipients are the 
powder bed. The API in the form of solution or suspension can also 
be jetted onto the powder bed [52]. 
Material jetting method 
A liquid formulation containing polymers, solution, suspension or 
UV curable resins can be jetted from the printer that solidifies 
rapidly and provides product geometry. It has 100 mm droplet size 
that gave it more resolution. The researchers have adopted this 
technology to make micro particles for drug delivery system [10]. 
Extrusion method 
Material is extruded from the automated nozzle onto the substrate. 
As in powder bed deposition, it does not have powder bed and 
require higher support material. The materials that can be extruded 
are molten polymers, suspensions, semisolids, pastes [5]. 
Powder bed fusion method 
As the name indicates, it involves the fusion or binding of low 
melting point with high melting point binders. The laser beam 
supplies the heat required for the binding. It is a rapid process, but 
comparatively more complex than extrusion method [52]. 
Photo polymerisation method 
It includes the polymerisation reaction between the liquid resins on 
exposure to UV or high energy light source. It requires 
photopolymerizable raw material for pharmaceutical 
manufacturing. An example of drug delivery application is 3D 
printing of photopolymerizable hydrogels [52]. 
Pen based 3DP method 
In this process, the layer by layer assembly is manually controlled 
with hand held device [53]. 
Direct energy deposition method 
In this process the raw materials are melted by a laser or electron 
beam energy sources as they are deposited. This method uses the 
material that cannot be extruded such as powder or other raw 
materials [53]. 
Sheet lamination method 
It is an automated laser-cutting and sheet-by-sheet assembly of 
products. This process is quick and inexpensive although it has low-
resolution and more useful than most printing methods [53]. 
Pharmaceutical potentials of 3D printing 
The processes that are traditionally adopted by pharmaceutical 
industries such as milling, mixing, granulation and compression 
sometimes results in uneven qualities of the final products 
depending on the factors such as drug loading, drug release, drug 
stability and pharmaceutical dosage form stability. On the other 
hand, 3D printing, as a powerful tool technology, has competitive 
advantages such as improved R and D productivity, improved safety, 
efficacy and accessibility of medicine [5]. The major advantages of 
3D printing that makes it much more attracting are:  
Personalised medication 
Some patients respond differently to same drugs. 3DP could help the 
physician or the pharmacist to produce the optimal dose of 
medication as per their age, race and gender. Furthermore, it allows 
the formation of single pill containing layers of multiple ailments 
that the patients need for the treatment [4].  
Tailored medication 
3D printing allows the production of medication as per the required 
needs of the patients. In case of pediatrics dose, the range of dose 
may vary and hence, this method can be easily adopted. Similarly, 
the shape of the dosage form can be altered for the patients with 
swallowing difficulties. 3DP is highly flexible and simple method to 
change the shape and size of the dosage form [54].  
Create complex shapes 
3DP allows formations of complex shapes and that too with accurate 
dose of medication or API, even as low as 10-12 mole tablets which 
helps in reducing the side effects that are seen due to excessive 
doses. As compared to conventional methods where complex 
geometries were not possible it can be achieved easily by 3D 
printing. Similarly, different shapes and sizes also results in different 
release profile. Complex shapes results in modified release, adjust 
drug loading and mask the taste of the medication [54].  
Sustained release 
Drug release can be easily controlled and targeted by 3D printing. It 
can be adopted by printing a binder in the layers of the matrix 
powder. This creates a barrier between the layers of API and allows 
variation in release profile. 
Unique dosage form 
In pharmaceutical production process, 3D printing can be used to 
create unique and limitless dosage forms. 3DP is used to create novel 
dosage forms [55].  
Mini dispenser unit 
The set up for 3D printers require minimal space allowing them to fit 
in any environment, are cost effective. 3D printing is a computer 
aided design that means it can be controlled using computer 
software and network. Moreover, 3D printing technologies allows 
individualization of medication. These characteristics allows 3D 
printer to function as a mini-dispenser to potentially bring tablet 
manufacturing closer to patients [54].  
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Integrated with health care network 
Physicians and pharmacists can modify the next dose or drug 
combinations according to patient’s need. As 3D printers are 
remotely controlled, 3D printing can became easily accessible to the 
patients. Hence, this improves the patients’ compliance and shortens 
the time of clinical response to patient’s needs [54].  
Accelerated disintegration 
3D printing makes a huge difference with powder compression in 
terms of disintegration process. The pattern of powder aggregation 
is different in both the conventional and newer method. In 3D 
printing powder binding strength is higher in the periphery and 
lowers in the centre which leads to rapid disintegration of tablets. 
Aprecia's Zip Dose® has found to disintegrate in less than 10s whilst 
containing a high dose of piracetam (1000 mg) [54].  
Tool less 
3DP can eliminate the need for tool production and therefore, 
reduced cost, lead time and labour associated with it.  
Sustainable/eco friendly 
3D printing being a new and emerging technology is energy-efficient 
and provides environmental efficiencies. It utilises up to 90% of 
standard materials, and, therefore, creates less waste. It has stronger 
design that imposes a reduced carbon footprint compared with 
traditionally manufactured products. 
Short production time 
3D printers are time efficient which shortens the product 
development design cycles. 
Manufacturing process 
The manufacturing process is quite easier and cost effective. The 
time of processing is less due to improved tools, less waste and takes 
fewer steps to assemble the setup and also reduce lead time via 
functional integration of parts.  
Engineering and maintenance 
3D printers have more flexible set up and maintenance processes. It 
is cost-efficient industrial engineering. 
Logistic 
3D printing is promising tool whereby products can be 
manufactured on demand and place where needed which reduces 
the inventory and logistics handling and moreover the 
transportation and related costs [5]. 
  
Table 1: Fabrication of dosage forms by 3D printing technology 
3D printing Dosage form Drug Reference 
FDM Catheter Nitrofurantoin [56] 
FDM Implant CR Dye [57] 
FDM General Device Gentamicin sulphate, Methotrexate [58] 
FDM Implant Nitrofurantoin, Hydroxyapatite [59] 
FDM Tablet ER Prednisolone [5] 
FDM Tablet MR Acetaminophen [60] 
FDM Capsule-shaped tablets Budesonide [61] 
FDM Capsules IR, MR Acetaminophen, Furosemide [6] 
FDM Tablet (IR, SR) Pravastatin, Atenolol, Ramipril, 
Aspirin, Hydrochlorothiazide 
[62] 
FDM Tablet Fluorescein [63] 
FDM Tablet (MR) 5-aminosalicylic acid and 4-
aminosalicylic acid 
[64] 
FDM T-shaped (IU, SC rods) Indomethacin [65] 
FDM Tablets (IR) 5-Aminosalicylic acid, Captopril, 
Theophylline and Prednisolone 
[66] 
Thermal Inkjet printer Tablet Prednisolone [67] 
Inkjet Printing Implant Levofloxacin [55] 
Thermal inkjet printer Solution Salbutamol [68] 
Inkjet printing nanoparticles Rifampicin [69] 
Thermal inkjet printer Solid dispersion Felodipine [70] 
Thermal inkjet printer Nano suspension Folic acid [71] 
Desktop 3D printer Tablet Guaifenesin [72] 
A lab-scale 3DP machine Capsule Pseudoephedrine HCl [5] 
3DP Tablet Acetaminophen [73] 
3DP Multi-drug implant Rifampicin, Isoniazid [5] 
Extrusion printing Tablet Captopril, Nifedipine, Glipizide [40] 
3D printer Microfluidic pump Saline solution [74] 
3D printer Fast-disintegrating Paracetamol [75] 
Electro hydrodynamic atomization technique Patterned micron scaled 
structures 
Tetracycline hydrochloride [76] 
Stereolithography 3DP Tablets (MR) 4-aminosalicylic acid and 
Paracetamol 
[77] 
3D printer Capsule-shaped solid devices Acetaminophen and Caffeine [78] 
3D printer Biodegradable patch 5-Fluorouracil [79] 
3D printer Microporous bioceramics Tetracycline, Vancomycin, 
Ofloxacin 
[80] 
3D printer Oral pulsatile tablet Chlorpheniramine maleate, 
Diclofenac sodium 
[81] 
Extrusion printer Drug encapsulated film of 
PLGA and PVA 
Dexamethasone [82] 
Stereolithography printer Anti-acne patch Salicylic acid [83] 
3D printer Tablets Paracetamol [84] 
Piezoelectric inkjet printer Microparticles Paclitaxel [85] 
CR-controlled release, IR-immediate release, MR-modified release, ER-extended release, IU-Intrauterine, SC-Subcutaneous 
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Worldwide: USA-FDA approved 3D printed drug product  
In August 2015, Aprecia pharmaceuticals introduced the first drug 
product using the ZipDose technique for the treatment of epilepsy. 
FDA approved the drug product SPRITAM levetiracetam for oral use 
for the treatment of partial seizures, primary generalized tonic 
clonic seizures, myoclonic seizures in adults and children. Spritam 
was formulated by ZipDose technology that produced a porous 
formulation that disintegrates rapidly. Spritam was designed to fill 
the needs of the patients who have problems with the current 
medication therapy. ZipDose technology enables the incorporation 
of large doses upto 1000 mg in single dosage form. This technology 
enhanced the patient compliance by easy administration of drug. 
ZipDose technology combines the drug formulation science with 
unique manufacturing capabilities of 3D printing. Aprecia 
pharmaceuticals have the FDA approved licence for developing the 
pharmaceutical dosage form worldwide [10].  
CONCLUSION 
3D printing technology is a growing trend towards advanced drug 
delivery. This technology has the built-in flexibility of personalized 
and customized medicines. Moreover, it may transform the 
conventional pharmacy practice by allowing medications to be truly 
individualized to a patient. Furthermore, it enables preparation of 
dosage forms with accurate dose, shape and size control. It can be 
assumed that in coming era 3DP can revolutionize the 
manufacturing processes of pharmaceutical formulations with 
improved safety and efficacy. 
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